Millions of people are living with Alzheimer's disease, a progressive, irreversible brain disorder that causes cognitive decline, confusion, memory loss, and many other symptoms. The Alzheimer's Assoc ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

“Choosing a meaningful gift for someone living with dementia requires thoughtful consideration,” said Stacie Kulp, executive director of the Alzheimer’s Association of Utah, in a written statement.

Alzheimer's disease often begins many years before memory problems appear. During that silent phase, toxic changes slowly ...

An oral version of the GLP-1 drug semaglutide failed to significantly slow the disease's progression compared to a placebo.

November is Alzheimer’s Awareness Month and the Oklahoma chapter of the Alzheimer’s Association is working to make sure families have the tools they need.

GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the ...

News about Alzheimer's rose to the forefront in 2025, as the FDA approved the first diagnostic blood test and drugmakers ...

Despite encouraging biomarker shifts, oral semaglutide failed to slow cognitive decline in early Alzheimer’s, leading to an ...

Novo Nordisk's closely watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the ...

More than 300 people participated in this year's walk, which raised about $66,000 for the Alzheimer's Association.